Last 7 days
3.8%
Last 30 days
-20.1%
Last 90 days
-18.4%
Trailing 12 Months
-16.2%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
SYK | 110.8B | 19.0B | -8.78% | 16.43% | 46.98 | 6.01 | 8.73% | 30.37% |
MDT | 108.4B | 30.8B | -9.46% | -17.45% | 26.61 | 3.52 | -3.19% | -17.32% |
ISRG | 107.5B | 6.4B | 4.05% | 37.44% | 81.96 | 16.72 | 8.89% | -20.19% |
BDX | 71.3B | 18.8B | -6.73% | -3.13% | 44.09 | 3.79 | -1.96% | -15.83% |
EW | 49.7B | 5.5B | -6.18% | -16.80% | 33.38 | 9.03 | 2.68% | -3.23% |
MID-CAP | ||||||||
SWAV | 7.2T | 557.2M | -1.64% | 66.40% | 82.2K | 16.8K | 86.42% | 730.06% |
PEN | 11.7B | 884.6M | 7.85% | 115.97% | 1.8K | 13.2 | 13.08% | 200.12% |
GMED | 5.9B | 1.1B | -8.20% | -19.98% | 34.14 | 5.75 | 11.20% | 53.04% |
IRTC | 3.6B | 430.0M | -11.89% | -12.63% | -34.73 | 8.45 | 26.13% | 15.73% |
TNDM | 1.7B | 794.7M | -29.15% | -60.56% | -8.43 | 2.16 | 7.73% | -3556.34% |
SMALL-CAP | ||||||||
SILK | 1.2B | 150.7M | -30.80% | 0.49% | -21.65 | 7.87 | 40.31% | 1.80% |
AVNS | 1.1B | 814.3M | -20.14% | -16.22% | 24.47 | 1.34 | 6.96% | 121.89% |
BLFS | 974.0M | 163.2M | 25.14% | 71.36% | -6.65 | 5.97 | 17.84% | -885.82% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | -0.7% | 814 | 820 | 796 | 778 | 761 |
Gross Profit | -0.8% | 446 | 450 | 431 | 411 | 382 |
S&GA Expenses | 0.8% | 345 | 342 | 335 | 327 | 317 |
R&D Expenses | 0.3% | 31.00 | 31.00 | 31.00 | 32.00 | 32.00 |
EBITDA | 3.2% | 123 | 119 | 101 | 62.00 | - |
EBITDA Margin | 0.2% | 0.15* | 0.15* | 0.13* | 0.08* | - |
Earnings Before Taxes | -11.8% | 58.00 | 65.00 | 68.00 | 54.00 | 29.00 |
EBT Margin | -6.4% | 0.08* | 0.08* | 0.07* | 0.04* | - |
Interest Expenses | 22.0% | 12.00 | 10.00 | 8.00 | 6.00 | 4.00 |
Net Income | -11.7% | 45.00 | 51.00 | 45.00 | -5.90 | 20.00 |
Net Income Margin | 8.7% | 0.06* | 0.06* | -0.01* | 0.02* | - |
Free Cahsflow | -16.8% | 91.00 | 109 | 104 | 92.00 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -2.9% | 1,735 | 1,787 | 1,775 | 1,753 | 1,767 |
Current Assets | -9.2% | 454 | 500 | 470 | 437 | 439 |
Cash Equivalents | -25.1% | 96.00 | 128 | 117 | 107 | 104 |
Inventory | 5.1% | 200 | 190 | 194 | 169 | 158 |
Net PPE | -0.2% | 164 | 164 | 163 | 164 | 167 |
Goodwill | 0.3% | 822 | 819 | 824 | 825 | 826 |
Liabilities | -12.0% | 436 | 496 | 512 | 501 | 510 |
Current Liabilities | -14.7% | 159 | 186 | 162 | 151 | 153 |
Long Term Debt | -0.6% | 248 | 249 | 254 | - | - |
LT Debt, Current | 0% | 6.00 | 6.00 | 6.00 | 5.00 | - |
LT Debt, Non Current | - | 226 | - | - | - | - |
Shareholder's Equity | 0.6% | 1,299 | 1,291 | 1,264 | 1,259 | 1,263 |
Retained Earnings | -0.2% | -253 | -253 | -270 | -293 | -304 |
Additional Paid-In Capital | 0.3% | 1,651 | 1,646 | 1,642 | 1,637 | 1,633 |
Accumulated Depreciation | 2.1% | 149 | 146 | 142 | - | - |
Shares Outstanding | 0.3% | 47.00 | 47.00 | 46.00 | 47.00 | 47.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -9.5% | 82.00 | 91.00 | 109 | 104 | 92.00 |
Share Based Compensation | 1.3% | 16.00 | 16.00 | 15.00 | 14.00 | 14.00 |
Cashflow From Investing | 86.9% | -17.70 | -135 | -135 | -135 | -137 |
Cashflow From Financing | -225.4% | -71.10 | 57.00 | 53.00 | 44.00 | 51.00 |
Buy Backs | -40.2% | 27.00 | 46.00 | 56.00 | 45.00 | 31.00 |
89.2%
82.3%
46.1%
Y-axis is the maximum loss one would have experienced if Halyard Health was unfortunately bought at previous high price.
-1.2%
-3.8%
-15.4%
-7.6%
FIve years rolling returns for Halyard Health.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-23 | Front Row Advisors LLC | unchanged | - | - | 2,000 | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 6.11 | 1,549,650 | 10,880,600 | -% |
2023-05-22 | PUTNAM INVESTMENTS LLC | reduced | -4.06 | 47,921 | 929,346 | -% |
2023-05-19 | CHELSEA COUNSEL CO | sold off | -100 | -135 | - | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 10.16 | 531,665 | 3,057,660 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -37.65 | -479,000 | 1,042,000 | -% |
2023-05-17 | Thrivent Financial for Lutherans | reduced | -1.99 | 170,000 | 2,366,000 | 0.01% |
2023-05-17 | VIRGINIA RETIREMENT SYSTEMS ET AL | new | - | 270,600 | 270,600 | -% |
2023-05-17 | Advisory Services Network, LLC | reduced | -47.54 | -1,398 | 1,903 | -% |
2023-05-17 | Sunbelt Securities, Inc. | new | - | 604 | 604 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | rgm capital, llc | 5.71% | 2,653,104 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 11.83% | 5,500,000 | SC 13G/A | |
Feb 08, 2023 | paradice investment management llc | 5.0% | 2,343,232 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 16.3% | 7,571,048 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 16.3% | 7,571,048 | SC 13G | |
Feb 14, 2022 | price t rowe associates inc /md/ | 0.2% | 133,980 | SC 13G/A | |
Feb 11, 2022 | champlain investment partners, llc | 2.44% | 1,174,483 | SC 13G/A | |
Feb 11, 2022 | rgm capital, llc | 6.08% | 2,930,872 | SC 13G | |
Feb 09, 2022 | vanguard group inc | 10.84% | 5,221,786 | SC 13G/A | |
Feb 04, 2022 | wellington management group llp | 2.75% | 1,325,674 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 21.22 -9.28% | 26.07 11.46% | 32.29 38.05% | 54.97 135.01% | 69.04 195.17% |
Current Inflation | 20.16 -13.81% | 24.36 4.15% | 29.62 26.64% | 49.06 109.75% | 60.98 160.71% |
Very High Inflation | 18.84 -19.45% | 22.27 -4.79% | 26.43 13.00% | 42.15 80.21% | 51.61 120.65% |
Date Filed | Form Type | Document | |
---|---|---|---|
May 25, 2023 | SD | SD | |
May 09, 2023 | 4 | Insider Trading | |
May 09, 2023 | 4 | Insider Trading | |
May 09, 2023 | 4 | Insider Trading | |
May 03, 2023 | 10-Q | Quarterly Report | |
May 03, 2023 | 8-K | Current Report | |
Mar 23, 2023 | 4/A | Insider Trading | |
Mar 23, 2023 | 4/A | Insider Trading | |
Mar 17, 2023 | ARS | ARS | |
Mar 17, 2023 | DEF 14A | DEF 14A |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-08 | Woody Joseph Fralin | sold (taxes) | -1,372,430 | 23.97 | -57,256 | chief executive officer |
2023-05-08 | Greiner Michael | sold (taxes) | -352,599 | 23.97 | -14,710 | svp - chief financial officer |
2023-05-08 | Holbrook Kerr | sold (taxes) | -42,474 | 23.97 | -1,772 | svp, chief commercial officer |
2023-03-06 | Greiner Michael | acquired | - | - | 36,350 | svp - chief financial officer |
2023-03-06 | Holbrook Kerr | sold (taxes) | -44,815 | 29.62 | -1,513 | svp, gm chronic care |
2023-03-06 | James Mojirade | acquired | - | - | 20,339 | svp, general counsel |
2023-03-06 | Sarker Arjun Ranjan | acquired | - | - | 4,562 | senior vp, international |
2023-03-06 | Woody Joseph Fralin | sold (taxes) | -246,261 | 29.62 | -8,314 | chief executive officer |
2023-03-06 | Haydon William David | sold (taxes) | -44,815 | 29.62 | -1,513 | svp, gm pain franchise |
2023-03-06 | Varshney Sudhakar | acquired | - | - | 12,463 | svp, global supply chain |
CONDENSED CONSOLIDATED INCOME STATEMENTS - USD ($) $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||
Net Sales | $ 191.7 | $ 197.4 |
Cost of products sold | 87.2 | 90.8 |
Gross Profit | 104.5 | 106.6 |
Research and development | 7.9 | 7.8 |
Selling and general expenses | 92.7 | 90.1 |
Other expense, net | 1.3 | 0.1 |
Operating Income | 2.6 | 8.6 |
Interest income | 0.5 | 0.0 |
Interest expense | (3.5) | (1.3) |
(Loss) Income Before Income Taxes | (0.4) | 7.3 |
Income tax provision | (0.1) | (1.9) |
Net (Loss) Income | $ (0.5) | $ 5.4 |
(Loss) Earnings Per Share | ||
Basic (in dollars per share) | $ (0.01) | $ 0.11 |
Diluted (in dollars per share) | $ (0.01) | $ 0.11 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 95.7 | $ 127.7 |
Accounts receivable, net of allowances | 142.7 | 167.9 |
Inventories | 200.0 | 190.3 |
Prepaid and other current assets | 15.4 | 13.9 |
Total Current Assets | 453.8 | 499.8 |
Property, Plant and Equipment, net | 163.5 | 163.9 |
Operating Lease Right-of-Use Assets | 28.3 | 30.6 |
Goodwill | 821.5 | 819.4 |
Other Intangible Assets, net | 244.7 | 251.0 |
Deferred Tax Assets | 4.5 | 4.6 |
Other Assets | 18.6 | 17.6 |
TOTAL ASSETS | 1,734.9 | 1,786.9 |
Current Liabilities | ||
Current portion of long-term debt | 6.2 | 6.2 |
Current portion of operating lease liabilities | 12.1 | 12.8 |
Trade accounts payable | 59.6 | 67.9 |
Accrued expenses | 80.6 | 98.9 |
Total Current Liabilities | 158.5 | 185.8 |
Long-Term Debt | 204.7 | 226.3 |
Operating Lease Liabilities | 32.4 | 34.7 |
Deferred Tax Liabilities | 25.1 | 25.4 |
Other Long-Term Liabilities | 15.5 | 23.5 |
Total Liabilities | 436.2 | 495.7 |
Commitments and Contingencies | ||
Stockholders’ Equity | ||
Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued | 0.0 | 0.0 |
Common stock - $0.01 par value - authorized 300,000,000 shares, 46,660,199 outstanding as of March 31, 2023 and 46,528,907 outstanding as of December 31, 2022 | 0.5 | 0.5 |
Additional paid-in capital | 1,651.0 | 1,646.4 |
Accumulated deficit | (253.6) | (253.1) |
Treasury stock | (67.9) | (66.8) |
Accumulated other comprehensive loss | (31.3) | (35.8) |
Total Stockholders’ Equity | 1,298.7 | 1,291.2 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 1,734.9 | $ 1,786.9 |